Up to 20% of pharma brands moving digital media spend to point-of-care

Up to 20% of pharma brands moving digital media spend to point-of-care

Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.

Drugmakers turn to social — not TV — to market drugs to women

Drugmakers turn to social — not TV — to market drugs to women

Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.

Top 25 women's health brands, based on U.S. sales in 2016

Top 25 women's health brands, based on U.S. sales in 2016

Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.

Infographic | The leaders of the global hepatitis-C market

Infographic | The leaders of the global hepatitis-C market

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.

Why Sanofi's dengue fever vaccine fell short of expectations

Why Sanofi's dengue fever vaccine fell short of expectations

Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?

Top 25 vaccine products in 2016, based on U.S. sales

Top 25 vaccine products in 2016, based on U.S. sales

Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.

Investors put their money on point of care

Investors put their money on point of care

Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?

Study: Hiking the prices of heart drugs led to fewer sales

Study: Hiking the prices of heart drugs led to fewer sales

Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

What's holding back value-based pricing deals from moving beyond the pilot phase?